Despite Eli Lilly's announcement that its obesity medications will be listed on the formularies of major pharmacy benefit managers, actual coverage remains uncertain. Many health insurers and plan sponsors are reluctant to cover these weight-loss drugs, with some even reducing existing coverage. A Centers for Medicare and Medicaid Services initiative to expand access for seniors and disabled individuals has stalled due to low participation, indicating a general lack of appetite for increased coverage. AI
RANK_REASON Article discusses the complexities and uncertainties surrounding health insurance coverage for weight loss drugs, rather than announcing a new product or policy.
- Centers for Medicare and Medicaid Services
- CVS Caremark
- Eli Lilly
- Express Scripts
- Foundayo
- GLP-1s
- Medicaid
- Medicare
- Novo Nordisk
- OptumRx
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
